Estimated longevity benefit: +1.0 years. Evidence score: 60/100.
Canagliflozin is an SGLT2 inhibitor that promotes the excretion of glucose through the urine to lower blood sugar and insulin levels. This metabolic shift induces a state of caloric restriction mimicry that has demonstrated significant and reproducible lifespan extension in male animal models.